NewAmsterdam Historical Balance Sheet
| NAMSW Stock | 9.06 0.63 6.50% |
Trend analysis of NewAmsterdam Pharma balance sheet accounts such as Total Current Liabilities of 29.7 M provides information on NewAmsterdam Pharma's total assets, liabilities, and equity, which is the actual value of NewAmsterdam Pharma to its prevalent stockholders. By breaking down trends over time using NewAmsterdam Pharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining NewAmsterdam Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether NewAmsterdam Pharma is a good buy for the upcoming year.
NewAmsterdam Pharma Inventory |
|
NewAmsterdam |
About NewAmsterdam Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of NewAmsterdam Pharma at a specified time, usually calculated after every quarter, six months, or one year. NewAmsterdam Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of NewAmsterdam Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which NewAmsterdam currently owns. An asset can also be divided into two categories, current and non-current.
NewAmsterdam Pharma Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of NewAmsterdam Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in NewAmsterdam Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on NewAmsterdam Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of NewAmsterdam Pharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Most accounts from NewAmsterdam Pharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into NewAmsterdam Pharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NewAmsterdam Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.At this time, NewAmsterdam Pharma's Other Current Liabilities is fairly stable compared to the past year. Property Plant And Equipment Net is likely to climb to about 122.9 K in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 57 K in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 164K | 118K | 60K | 57K | Total Assets | 59.8M | 531.6M | 347.1M | 260.6M |
NewAmsterdam Pharma balance sheet Correlations
Click cells to compare fundamentals
NewAmsterdam Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.